Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-20-020043
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-03-18 17:08:39
Reporting Period:
2020-03-16
Accepted Time:
2020-03-18 17:08:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1510487 Principia Biopharma Inc. PRNB Pharmaceutical Preparations (2834) 263487603
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1751790 Stefani Wolff C/o Principia Biopharma Inc.
220 E. Grand Avenue
South San Francisco CA 94080
Chief Development Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-03-16 5,504 $4.54 41,113 No 4 M Direct
Common Stock Disposition 2020-03-16 1,754 $45.72 39,359 No 4 S Direct
Common Stock Disposition 2020-03-16 3,750 $46.36 35,609 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2020-03-16 5,504 $0.00 5,504 $4.54
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
19,047 2027-02-15 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  2. Represents the weighted average sales price per share. The shares sold at prices ranging from $45.05 to $46.01 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  3. Represents the weighted average sales price per share. The shares sold at prices ranging from $46.08 to $46.60 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  4. The stock option vested and became exercisable as to 25% of the shares subject to the option on July 1, 2017, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.